Article Text

Download PDFPDF

Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age
Free
  1. C S Devulapalli1,2,
  2. K C L Carlsen1,3,
  3. G Håland1,
  4. M C Munthe-Kaas1,3,
  5. M Pettersen2,
  6. P Mowinckel1,
  7. K-H Carlsen2,3
  1. 1
    Department of Paediatrics, Division of Woman and Child, Ullevål University Hospital, Oslo, Norway
  2. 2
    Voksentoppen, Department of Paediatrics, Rikshospitalet-Radiumhospitalet Medical Centre, Oslo, Norway
  3. 3
    The Medical Faculty, University of Oslo, Oslo, Norway
  1. Dr K-H Carlsen, Voksentoppen, Department of Paediatrics, Rikshospitalet-Radiumhospitalet Medical Centre, Oslo, University of Oslo, NO-0791 Oslo, Norway; k.h.carlsen{at}medisin.uio.no

Abstract

Background: Predicting school-age asthma from obstructive airways disease (OAD) in early life is difficult, even when parental and children’s atopic manifestations are taken into consideration.

Objective: To assess if the severity of OAD in the first 2 years of life predicts asthma at 10 years of age.

Methods: From a nested case control study within the Environment and Childhood Asthma study, 233 2-year-old subjects with recurrent (⩾2 episodes) bronchial obstruction (rBO+) and 216 subjects without bronchial obstruction (rBO−) underwent clinical examination, parental interview, treadmill test and metacholine bronchial hyperresponsiveness (BHR) measurement at 10 years. A severity score at 2 years was calculated by frequency, persistence of bronchial obstruction and hospital admissions because of OAD.

Main outcomes: Current asthma at 10 years (asthma with symptoms and/or asthma medication during the past year and/or positive treadmill test). Secondary outcome was metacholine BHR at 10 years.

Results: Compared with rBO− subjects, adjusted odds ratio (95% CI) of current asthma among rBO+ was 7.9 (4.1, 15.3), and among rBO+ with a severity score of >5, 20.2 (9.9, 41.3). In receiver operated characteristic analysis, positive and negative predictive values demonstrated the applicability and value of the score, with an optimal cut-off at severity score 5. Children with severity score >5 had severe BHR more often (PD20 metacholine <1 μmol) than children with a lower or 0 score (p = 0.0041).

Conclusion: Using a simple scoring system, a high severity score of OAD by 2 years of age is a strong risk factor for, and may predict, current asthma at 10 years of age.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The majority of school children with asthma have asthma-like symptoms during the first few years of life. However, predicting asthma at school age from wheezing illness in early life is challenging as the aetiology of wheezy lower respiratory tract disease in early childhood is heterogeneous.13 Children with severe asthma are more likely to require emergency medical visits, hospital admissions and often have reduced quality of life.4 Early life events may influence later respiratory illness,5 and we have recently reported the association between reduced lung function at birth and current asthma and severe bronchial hyperresponsiveness at 10 years of age.6

Clough and colleagues7 developed models to predict 12 months of persistent wheezing in infant wheezers, with maximal predictive value of 78%, including personal atopy, parental atopy, age and cytokine studies. From the Tucson Children’s Respiratory Study, Castro-Rodriguez et al8 developed two clinical indices at 3 years of age to define risk of asthma at school age. They found active asthma on at least one occasion between 6 and 13 years in 76% and 59% of children with their positive stringent and loose index models, respectively. Their indices included characteristics of wheezing at 0–3 years, doctor diagnosed parental asthma or eczema, eosinophilia or allergic rhinitis. However, despite the increased risk of later asthma among hospital admitted young children with obstructive airways disease (OAD),9 none of these studies7 8 10 included severity of (frequency and/or persistence) and/or hospital admissions for OAD in their models.

Early identification of children at risk of persistent asthma in childhood may improve follow-up of children at risk. The main objective of the present study was to assess if the severity of OAD during the first 2 years of life predicts current (ongoing) asthma at 10 years of age.

METHODS AND SUBJECTS

Study design and subjects

The present study is part of the 10 year follow-up of the Environment and Childhood Asthma study in Oslo.11 Briefly, a cohort of 3754 newborns was established at birth in Oslo over 15 months starting from 1 January 1992 when parents completed the first of five half yearly questionnaires until the child’s second birthday. Questions included family history of allergic and other diseases, environmental exposures (including parental smoking habits and pet keeping), health of the child (respiratory, allergic, skin as well as general diseases) and details of any medical treatment.11 The study was approved by the Regional Committee for Medical Ethics and the Norwegian data inspectorate. Written informed consent was obtained from parents of all subjects.

A nested case control study was established based on the children participating in the birth cohort study11 12 to perform detailed examinations of children with recurrent (⩾2 episodes of or ⩾4 weeks (persistent)) doctor confirmed bronchial obstruction (BO) by their second birthday (cases or rBO+) (n = 306) and the child born closest in time without BO by 2 years of age (rBO−) (n = 306). Recruitment strategies to identify all rBO+ children have been reported previously.11 12

The 2 year clinical visit was attended by 516/612 eligible children, 265 rBO+ and 251 rBO− children, respectively (fig 1).

Figure 1 The Environment and Childhood Asthma study in Oslo; subjects from birth to 10 years in the present study. Cases* (rBO+) were defined as children who had at least two episodes or a minimum of 4 weeks persisting, doctor confirmed, bronchial obstruction and controls** (rBO−) were age matched children without bronchial obstruction by 2 years of age. Sufficient data were available for assessment of severity score at 2 years as well as current asthma at 10 years of age in 233/239 rBO+ children and 216/220 rBO− children.

The present study reports the results from the 10 year follow-up study of the nested case control population only, with a follow-up rate of 89%, including 239 rBO+ and 220 rBO− subjects (fig 1). The 459 attendees and the 57 non-attendees did not differ significantly in relation to gender, parental atopy, age, weight or height at 2 years (data not shown). However, because of insufficient data at 2 and/or 10 years in 10 children, the present study included the 449 children (233 rBO+ and 216 rBO− subjects) with complete data to calculate severity score at 2 years and current asthma at 10 years (fig 1).

Two year clinical visit

A parental structured interview was performed by the study doctor, including details of diseases of the index child and primary family members, infections, environmental exposures, housing, socioeconomic factors and any type of medical treatment. Severity of OAD was assessed by the questions: “has the child ever had wheezing and/or shortness of birth?”, if yes, “the number of episodes with wheezing” and/or “the number of months with persistent wheezing” and “was the child ever admitted to hospital due to wheezing?” and if yes, “the number of hospital admissions for wheezing”.

The skin prick test was performed according to the Nordic standard13 to the following allergens: cow’s milk, and the following standardised (ALK SQ): egg white, dermatophagoides pteronyssinus, timothy grass, cat dander, dog dander, silver birch, mugwort and cladosporium herbarum, as well as negative control solution and histamine control (10 mg/ml). Sensitisation was regarded as positive with an allergen weal of at least half the size of the histamine weal. Parental atopy by 2 years of age was defined as asthma and/or rhinoconjunctivitis reported in at least one parent.

Severity score

A severity score was calculated based on the clinical criteria present from 0 to 2 years of age: number of episodes of BO, number of months with persistent BO and number of hospital admissions due to BO (fig 2). Maximum score for an individual was 12. Two rBO− subjects had a severity score of 1 whereas the remaining subjects (n = 214) had a severity score of 0. The severity score was also calculated for patients at 12 months of age based on questionnaire data obtained every 6 months from birth to 2 years of age.

Figure 2 Severity score for obstructive airways disease. Criteria for severity score by 2 years of age. BO, bronchial obstruction. Maximum score is 12.

Ten year follow-up visit

At the 10 year visit,14 the study doctors conducted parental structured interviews regarding the child’s symptoms of asthma and asthma management, including validated questions from the International Study of Asthma and Allergies in Children.

Forced expiratory flow volume loops were measured according to European standards15 (reference values of Zapletal and colleagues16 with a SensorMedics Vmax 20c (SensorMedics Diagnostics, Yorba Linda, California, USA)).

Bronchial hyperresponsiveness (BHR) was measured after withholding short and long acting β2 agonists for at least 12 and 48 h, respectively, and leucotriene antagonists for 72 h, by methacholine challenge test performed the first day and by exercise challenge (treadmill run) within 1 week.

Methacholine challenge test was performed according to international guidelines17 by inhalation of doubling doses of methacholine, nebulised by the Spira nebuliser (Spira Respiratory Care Centre Ltd, Hämeenlinna, Finland), until reaching a cumulated dose of methacholine causing a reduction in forced expiratory volume in the first second (FEV1) of 20% (PD20 methacholine) or reaching the maximum cumulated dose (PD20) of 22.4 μmol methacholine.

A standardised exercise challenge test included running for 6–8 min on a motor driven treadmill (Woodway; Woodway GmbH, Weil am Rhein, Germany) (inclination of 5.5%), with increasing speed during the first 2 min to reach a heart rate of 95% of estimated maximum.18 FEV1 was measured before, and 3, 6, 10 and 15 min after running. The exercise challenge test was considered positive with ⩾10% fall of baseline FEV1 3–20 minutes after running ceased.

The skin prick test performed the first day of the 10 year follow-up visit is not reported, as outcome is related only to the events during 0–2 years of age.

Outcomes

The main outcome was current asthma at 10 years of age (table 1).14 Secondary outcome was non-specific BHR to metacholine (PD20).

Table 1 Definitions of the main outcome in the present study

Statistical analysis

Continuous variables are presented as mean (SD) and binary variables as counts with percentage. Two sample t tests and Pearson’s χ2 test were used to assess differences between rBO+ and rBO− and subjects with and without current asthma for continuous and categorical variables, respectively.

The risk of current asthma at 10 years of age was assessed using logistic regression analysis comparing rBO+ subjects with severity scores 1–12 and rBO− subjects. Results are given as odds ratios (OR) with 95% CI. The appropriateness of the logistic model was assessed using Hosmer and Lemeshow goodness of fit statistic.19 Dfbetas (defined as the change in the estimated parameters when the individual observation is deleted) and C–bar (a scalar measure of the influence of individual observations) statistics were used to assess the influence of an individual observation on each estimated parameter in the fitted model. Difference in deviance and χ2 were used to detect ill-fitted observations.19 Linearity of severity score as a continuous variable was assessed using Hosmer’s procedure.19 It was not feasible to perform logistic regression separately based on gender because of questionable model fit. Atopic dermatitis and allergic skin sensitisation at 2 years were included in the model as possible confounders.

Receiver operated characteristic (ROC) analysis was performed using the severity score 1–12 at 2 years and classification by current asthma at 10 years of age as clinical outcome. Sensitivity (probability (%) of a positive test result when the disease is present), specificity (probability (%) of a negative test result when the disease is not present), positive predictive value (probability (%) that the disease is present with a positive test) and negative predictive value (probability (%) that the disease is not present with a negative test) of severity scores were calculated. The prediction models of loose and stringent indices suggested by Castro-Rodriguez and colleagues8 were approximated to similar data in the present study, and predictive capacities were compared with our severity score.

A p values of ⩽0.05 was considered statistically significant. Calculations were performed with Statistical Package for Social Sciences (SPSS) V.12.0 for Windows and Statistical Analysis System (SAS) V.9.13.

RESULTS

Baseline demographic data and parental atopy for the 449 children (242 boys and 207 girls) included in the study (fig 1) were similar for the rBO+ children with (n = 233) and without (n = 6) and for the rBO− children with (n = 216) and without (n = 4) sufficient data to assess current asthma (data not shown). Mean (SD) age at the 10 year visit was 10.3 (0.7) years.

At the 2 year visit, rBO+ subjects were slightly younger, more frequently reported parental atopy (both p<0.001) and atopic dermatitis (p = 0.022) and were slightly shorter (p = 0.005) than rBO− children (table 2). At 10 years, weight, length and age did not differ significantly between rBO+ and rBO− subjects (table 2).

Table 2 Characteristics of the subjects (n = 449) in the present study

Current asthma at 10 years of age

Current asthma at 10 years was significantly more frequent among rBO+ (n = 85, 36.5%) compared with rBO− subjects (n = 12, 5.6%) (p<0.001). rBO+ children with compared with those without current asthma were not significantly different with respect to age, weight or height at 2 and 10 years, or atopic dermatitis, parental atopy or allergic skin sensitisation at 2 years (table 3). However, rBO+ children with current asthma (at 10 years) were more often hospitalised due to BO by 2 years of age (p = 0.01) (table 3) than rBO+ children without current asthma. More boys than girls had current asthma at 10 years (p = 0.05) (table 3).

Table 3 Characteristics of children with recurrent bronchial obstruction (rBO+) by 2 years of age related to the presence of current asthma at 10 years (n = 233)

Severity score

The severity score distribution at 2 years is shown in fig 3. The mean (95% CI) severity score of all rBO+ subjects at 2 years of age was 4.6 (4.2, 5.0), significantly higher among rBO+ children who developed current asthma (5.5 (4.9, 6.1)) compared with rBO+ children without current asthma (4.0 (3.6, 4.5); p<0.001) (table 3). The mean severity score at 12 months of age among rBO+ subjects was 1.04 (0.81, 1.27).

Figure 3 Distribution of severity score in children with recurrent bronchial obstruction (rBO+) at the age of 2 years (n = 233).

Risk of current asthma

Based on analysis of all children (n = 449), a linear association was found for severity score as a predictor for current asthma at 10 years; the OR for a 1 point increase in severity score was 1.35 (1.25, 1.45) and for a 2 point increase in severity score 1.82 (1.57, 2.11).

The unadjusted OR and adjusted OR for current asthma among all rBO+ children compared with rBO− children were 9.8 (5.1, 18.5) and 7.9 (4.1, 15.3), respectively (adjusted for gender, parental atopy and atopic eczema by 2 years of age as well as allergic skin sensitisation at the 2 year visit). Compared with rBO− children, the adjusted OR for current asthma was 20.2 (9.9, 41.3) for rBO+ children with severity scores of 6–12 at 2 years of age. Among rBO+ children, hospitalisation due to BO by 2 years of age caused only a slight increased risk of current asthma (OR 2.0 (1.1, 3.7)). By using the severity score calculated at the age of 12 months, the adjusted OR for current asthma at 10 years was 1.30 (1.11–1.52) (adjusted for gender, parental atopy) for a 1 point increase in severity score.

The ROC analysis for severity score at 2 years classified by current asthma at 10 years (curve not shown) revealed an area under the curve of 0.78 (95% CI 0.73, 0.83; p<0.0001). Adjusted OR and the results of the ROC analysis are shown in table 4 for each step of severity score, with sensitivity, specificity, positive and negative predictive values for current asthma. A score <3 and >5 had low and high specificity, respectively, for current asthma at 10 years (table 4).

Table 4 Odds ratio, sensitivity, specificity, positive and negative predictive values for predicting current asthma at 10 years of age in subjects at 2 years with severity scores at 2 years of age from 1 to 12, as well as approximated indices, as suggested by Castro-Rodriguez et al applied to our dataset8

The ROC analysis for severity score at 12 months, classified by current asthma at 10 years, revealed an area under the curve of 0.59 (0.54, 0.64; p = 0.007). However, with a cut-off value of severity score at 12 months set to 2 (identified as the best value), sensitivity was only 16.8 (9.9, 25.9), specificity 94.3 (91.3, 96.5), with a positive predictive value of 44.4 and negative predictive value of 80.6.

The predictive capacities for current asthma at 10 years of age compared with control children assessed by the stringent and loose indices reported by Castro-Rodriguez et al (originally calculated for children at the age of 3 years)8 were applied to comparable data in the present study, and the results are reported in table 4. Using a cut-off value above 5 in the present severity score at 2 years of age gave a higher positive predictive value (54.3), but similar negative predictive value (86.8) compared with the applied loose (87.7) and stringent (87.4) indices (table 4).

Bronchial hyperresponsiveness

Children with high severity scores at 2 years of age (above 5) had severe BHR (PD20 metacholine <1 μmol) significantly more often and mild or no BHR (PD20 metacholine >8 μmol) significantly less often compared with children with a severity score of 0 (control children) (p = 0.0041) (table 5).

Table 5 Distribution of patients according to severity score at 2 years and bronchial responsiveness to methacholine (PD20 methacholine) at 10 years of age

DISCUSSION

The present study demonstrates that a simple asthma severity score based on frequency and persistence of BO and hospitalisations for BO during the first 2 years of life predicts a higher risk for current asthma at 10 years of age. The almost linear association between severity score at 2 years and current asthma at 10 years suggests that prediction may be relevant for individual subjects, as well as on a group level.

Compared with the severity score at 2 years, a severity score calculated at 12 months of age, although a significant risk factor, had a poor predictive capability for current asthma 9 years later.

The high risk for current asthma at 10 years in children with higher severity scores at 2 years of age (mostly above 5) compared with children with no BO by 2 years of age, exceeds previously published reports.7 8 10 A severity score of 5 is not infrequent, reflecting two hospital admissions with one additional obstructive episode, or alternatively 5–6 episodes of BO with 1 month of persisting symptoms.

Dodge et al10 found ORs of 2.1 and 7.2 of having asthma up to 11 years in children who wheezed compared with non-wheezers at 1–2 years and 3–4 years of age, respectively. Although only among preschool children, Clough and coworkers7 found after 12 months of follow-up of 3–36-month-old children, that wheeze was more likely to persist in older, atopic infants with biparental atopy, and they detected asthma requiring prophylactic antiasthmatic treatment in 49.5% of children.

As one of few studies with reported clinical indices to predict asthma beyond 1–2 years, the Tucson study8 employed factors from 0 to 3 years of age to predict asthma at school age, including early wheeze and other allergic diseases, parental atopic disease and blood eosinophil count. The loose and stringent indices developed by Castro-Rodriguez et al8 were applied to data obtained before 3 years of age to detect active asthma during one of the surveys between 6 and 13 years of age. The ORs for active asthma at 11 years were 2.6 for the loose and 4.3 for the stringent indices, and for active asthma during at least one of the surveys (6–13 years) of 3.9 and 7.1, respectively.8 In the present population, the ORs of current asthma for children with a severity score above 5 compared with children with no BO was markedly higher (7.9) than when we applied the loose and stringent (6.4) indices suggested by Castro-Rodriguez et al. Furthermore, the positive predictive value (of current asthma) of the severity score at 2 years of >5 (as suggested by the ROC analysis) was 54.3, compared with 47.8 when applying the stringent index. Thus we believe that our simple scoring system based solely on a history of OAD by 2 years may be as suitable to predict current asthma 8 years later as the score which includes heredity and invasive laboratory tests, as well as a history of rhinitis with uncertain aetiology at this age.7 8

The predictability of our severity score at 2 years classified by current asthma at 10 years was demonstrated by a statistically significant area under the curve by ROC analysis. Such ROC curve analysis and calculation of sensitivity, specificity as well as positive and negative predictive values are used to assess the applicability of a diagnostic test. In both ours and the study by Castro-Rodriguez and coworkers,8 assessment of positive and negative predictive values demonstrated that scoring systems can be used to identify children with a high and low risk of active asthma in later childhood, and consequently that information obtained in early life may have a prognostic value for the patient. Applicability of the stringent and loose indices suggested by Castro-Rodriguez et al was demonstrated in a different study population than their own, whereas this remains to be demonstrated for our severity score. As both sets of scores include assessment of severity through the first years of life, they may to some extent corroborate each other and can be used with reasonable accuracy to predict which symptomatic infants are likely to have asthma during their school years.

The low predictability of the 12 month severity score in the present study may reflect the fact that many patients had not yet developed manifestations of obstructive airways disease. Also, the score at this point was constructed from data obtained in questionnaires only, with less detailed information than that obtained during parental interviews at 2 years.

Predictability of later disease may influence management strategies, and benefits of early anti-inflammatory treatment of asthma in school children has been discussed.20 However, recent randomised double blind placebo controlled trials in infancy,21 from infancy to 5 years of age22 and from preschool age23 have demonstrated improved symptom control and lung function during inhaled corticosteroid treatment, but not after cessation of such treatment. Thus decisions for corticosteroid treatment to improve long term outcome of asthma in individual patients based on prognostic scores may be inappropriate, whereas scores to suggest prognosis may be useful to identify children with special needs for closer follow-up and management of disease.

In the present study, parental atopy, atopic dermatitis as well as allergic skin sensitisation assessed at 2 years did not influence the risk of current asthma based on the severity score, and adjusted and unadjusted odds ratios were almost similar. However, the rBO children had a family history of atopy at 2 years similar to that in the studies by Castro-Rodriguez et al8 and Clough et al,7 whereas allergic skin sensitisation at 2 years, positive in very few children in the present study, was not assessed in the latter studies.

Strengths and limitations of the present study

In the present study, current asthma was defined by combining clinical diagnosis, current symptoms and current medication and an objective measure of exercise induced bronchoconstriction increasing the likelihood of selecting children with true persistent asthma and ongoing inflammatory airways disease.14

The prospective design with a longitudinal birth cohort study of children in a nested case control study and an 8 year follow-up rate of 89% limits the risk of recall bias at 10 years. Furthermore, the main outcome was current asthma at 10 years of age with symptoms present during the last year only which again minimises recall bias for the last 12 months. The study consequently focused on clinical presentation at the time of investigations (2 and 10 years), rather than the retrospective categorisation of “wheezing” phenotypes such as early onset transient wheeze, persistent wheeze and late onset wheeze.3

In conclusion, we have reported that a simple scoring system based on severity and frequency of OAD during the first 2 years of life predicted a higher risk for current asthma at 10 years of age. The simplicity of the symptom score renders it generally applicable for early identification of children at high risk of persistent asthma, with the possibility of subsequent consideration of relevant management strategies.

Acknowledgments

We are grateful to the children and parents participating in the study and to the research team involved in the clinical investigations of the follow-up study, especially to Solveig Knutsen, Ingebjørg Coward, Jorun Wikstrand, Trine Stensrud and Anne Cathrine Mork Wik.

REFERENCES

Footnotes

  • Funding: Grants from Norwegian Research Council, University of Oslo, the Norwegian Foundation for Health and Rehabilitation, Ullevål University Hospital, Health East (Regional Health Authority), the Norwegian Association of Asthma and Allergy, Voksentoppen, the Kloster Foundation and AstraZeneca.

  • Competing interests: None.